NASDAQ · Medical - Devices

ICCM (ICCM) Stock

$2.88 +3.23% NASDAQ: ICCM Healthcare

Valuation

MetricValue
Price$2.88
Market Cap$6.49M
P/E Ratio-1.00
P/B Ratio1.67
P/S Ratio4.12
EPS (TTM)$-0.24
52-Week High$42.00
52-Week Low$2.12
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-166.67%
ROA-107.14%
ROCE-166.67%
Gross Margin-500.00%
Operating Margin-500.00%
Net Margin-4.42%
Debt/Equity0.02
Current Ratio2.60

Annual Financials (USD)

Metric20212022202320242025
Revenue$4.0M$3.0M$3.0M$3.0M$3.0M
Operating Profit$-10.0M$-17.0M$-16.0M$-16.0M$-15.0M
Net Profit$-10.0M$-17.0M$-15.0M$-15.0M$-15.0M
EPS$-0.35$-0.47$-0.32$-0.30$-0.24
Op Margin-235.0%-542.6%-482.4%-476.9%-446.7%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$32.0M$30.0M$16.0M$13.0M$14.0M
Total Liabilities$5.0M$5.0M$4.0M$6.0M$5.0M
Cash$26.0M$24.0M$11.0M$8.0M$9.0M
Borrowings$1.0M$1.0M$1.0M$0$0

Latest News

IceCure Expands U.S. Commercial Team to Meet Surging Demand for ProSense® Cryoablation PR Newswire · Jul 14, 2026 IceCure Highlights Expanding Commercial Adoption of ProSense™ Cryoablation in Brazil Following FDA Clearance for Breast Cancer PR Newswire · Jul 6, 2026 IceCure Medical Files to Register Sale of 5.5 Million Shares by Armistice MT Newswires · Jun 25, 2026 IceCure Regains Compliance with Nasdaq Minimum Bid Price Requirement PR Newswire · Jun 25, 2026 IceCure Highlights New Peer-Reviewed Journal Article in Leading Surgery Journal, Demonstrating Cryoablation's Advantages Over Radiofrequency Ablation for Early-Stage Breast Cancer PR Newswire · Jun 23, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-13.0M$-14.0M$-13.0M$-13.0M$-15.0M
Investing Cash Flow$3.0M$-2.0M$-1.0M$0$0
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$22.0M$-2.0M$-13.0M$-3.0M$1.0M
Free Cash Flow$-13.0M$-15.0M$-13.0M$-13.0M$-15.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-104.44%
Quick Ratio1.97
Interest Coverage—
Return 1Y-88.12%
Return 3Y-90.91%
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BDMD $1.07 +1.42% -1.68 $45.16M 0.00%
CTSO $0.35 -4.32% -3.62 $22.25M 0.00%
ECORelectroCore, Inc. $6.02 -2.75% -3.42 $49.94M 0.00%
MDAISpectral AI, Inc. $1.67 +1.79% -3.10 $53.12M 0.00%
MDCX $0.28 -12.01% -0.71 $6.17M 0.00%

About ICCM

ICCM is led by CEO Eyal Shamir, employs 64 people, headquartered in IL, publicly traded since 2021.

ICCM stock trades at $2.88 with a market capitalization of $6.49M. The stock is valued at a price-to-earnings (P/E) ratio of -1.00, price-to-book of 1.67, price-to-sales of 4.12. Over the past 52 weeks the stock has ranged between $2.12 and $42.00, and currently trades 93.1% below its 52-week high.

On profitability, ICCM generates a return on equity (ROE) of -166.67%, return on capital employed of -166.67%, an operating margin of -500.00%, a net profit margin of -4.42%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides